The scientist’s investigation covers issues in Migraine, Anesthesia, Placebo, Randomized controlled trial and Chronic Migraine. His work carried out in the field of Migraine brings together such families of science as Tolerability, Clinical trial, Headaches and Intensive care medicine. He studies Cluster headache, a branch of Anesthesia.
His Placebo research includes themes of Clinical endpoint, Pharmacology and Subgroup analysis. Repeated measures design is closely connected to Adverse effect in his research, which is encompassed under the umbrella topic of Randomized controlled trial. He has included themes like Logistic regression, Discontinuation, Young adult, Standard of care and Severity of illness in his Chronic Migraine study.
Migraine, Anesthesia, Chronic Migraine, Internal medicine and Placebo are his primary areas of study. His Migraine study incorporates themes from Tolerability, Physical therapy, Clinical trial and Intensive care medicine. His study in Physical therapy is interdisciplinary in nature, drawing from both Alternative medicine and Neurology.
A large part of his Anesthesia studies is devoted to Cluster headache. David W. Dodick interconnects Pediatrics, Family medicine and Topiramate in the investigation of issues within Chronic Migraine. David W. Dodick combines subjects such as Clinical endpoint and Randomized controlled trial with his study of Placebo.
David W. Dodick spends much of his time researching Migraine, Internal medicine, Chronic Migraine, Placebo and Tolerability. His studies in Migraine integrate themes in fields like Adverse effect, Physical therapy, Clinical trial and Family medicine. David W. Dodick has researched Adverse effect in several fields, including Nausea and Anesthesia.
David W. Dodick focuses mostly in the field of Chronic Migraine, narrowing it down to topics relating to Medication overuse and, in certain cases, Sumatriptan. His studies deal with areas such as Subgroup analysis and Confidence interval as well as Placebo. The concepts of his Tolerability study are interwoven with issues in Second opinion and Pediatrics.
His primary areas of study are Migraine, Internal medicine, Chronic Migraine, Pediatrics and Tolerability. His Migraine research incorporates elements of Placebo, Clinical trial and Physical therapy. In general Internal medicine study, his work on Randomized controlled trial and Allodynia often relates to the realm of Serotonin Antagonists, thereby connecting several areas of interest.
His Pediatrics study combines topics in areas such as Migraine prophylaxis, Early onset and Onset of action. His Tolerability research incorporates themes from Second opinion, Reimbursement and Family medicine. His work on Morphine as part of his general Anesthesia study is frequently connected to Post-Traumatic Headache, thereby bridging the divide between different branches of science.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The International Classification of Headache Disorders, 3rd edition (beta version)
Jes Olesen;André Bes;Robert Kunkel;James W. Lance.
New Appendix Criteria Open for a Broader Concept of Chronic Migraine
J. Olesen;M -G Bousser;H -C Diener;D. Dodick.
A randomized trial of plasma exchange in acute central nervous system inflammatory demyelinating disease.
Brian G. Weinshenker;Peter C. O'Brien;Tanya M. Petterson;John H. Noseworthy.
Annals of Neurology (1999)
Narrative review: reversible cerebral vasoconstriction syndromes.
Leonard H. Calabrese;David W. Dodick;Todd J. Schwedt;Aneesh B. Singhal.
Annals of Internal Medicine (2007)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
HC Diener;DW Dodick;SK Aurora;CC Turkel.
OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double-Blind, Randomized, Placebo-Controlled Phases of the PREEMPT Clinical Program
David W. Dodick;Catherine C. Turkel;Ronald E. Degryse;Sheena K. Aurora.
Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society
S.D. Silberstein;S. Holland;F. Freitag;D.W. Dodick.
Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, parallel-treatment trial
Tony W Ho;Michel D Ferrari;David W Dodick;Vince Galet.
The Lancet (2008)
A self-administered screener for migraine in primary care: The ID Migraine™ validation study
Richard B. Lipton;D. Dodick;R. Sadovsky;K. Kolodner.
Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.
Stephen D. Silberstein;Richard B. Lipton;David W. Dodick;Frederick G. Freitag.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: